A European Medicines Agency (EMA) committee has adopted a positive opinion on Bavencio (avelumab), recommending its approval as a first-line maintenance treatment for adults with locally advanced or metastatic bladder cancer (urothelial carcinoma) who have not progressed after platinum-based chemotherapy. The opinion, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), will now be reviewed by the European Commission. A decision on Bavencio’s approval is expected early next year. “With this positive opinion,…
You must be logged in to read/download the full post.
The post EU Approval Urged for Bavencio as Maintenance Therapy for Bladder Cancer appeared first on BioNewsFeeds.